vs
Side-by-side financial comparison of ADMA BIOLOGICS, INC. (ADMA) and TRIMAS CORP (TRS). Click either name above to swap in a different company.
TRIMAS CORP is the larger business by last-quarter revenue ($256.5M vs $139.2M, roughly 1.8× ADMA BIOLOGICS, INC.). ADMA BIOLOGICS, INC. runs the higher net margin — 35.5% vs 31.9%, a 3.6% gap on every dollar of revenue. On growth, ADMA BIOLOGICS, INC. posted the faster year-over-year revenue change (18.4% vs 3.8%). TRIMAS CORP produced more free cash flow last quarter ($36.8M vs $34.6M). Over the past eight quarters, ADMA BIOLOGICS, INC.'s revenue compounded faster (30.4% CAGR vs 3.3%).
ADMA Biologics Inc. is a biopharmaceutical enterprise focused on the research, development, manufacturing and commercialization of specialty plasma-derived immunoglobulin therapies. It primarily operates in the United States, catering to patients with primary immunodeficiency and other immune-related disorders, healthcare providers and medical institutions across its core immune health therapeutic segment.
Trimas Corp is a diversified industrial manufacturing enterprise that designs, produces and distributes a wide portfolio of engineered products, including specialized fasteners, aerospace components, custom packaging solutions, and consumer & industrial hardware. It primarily serves aerospace, automotive, construction, consumer goods and industrial sectors, with core operations across North America and selected global markets.
ADMA vs TRS — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $139.2M | $256.5M |
| Net Profit | $49.4M | $81.7M |
| Gross Margin | 63.8% | 12.8% |
| Operating Margin | 45.1% | 5.7% |
| Net Margin | 35.5% | 31.9% |
| Revenue YoY | 18.4% | 3.8% |
| Net Profit YoY | -55.9% | 236.9% |
| EPS (diluted) | $0.20 | $2.03 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $256.5M | ||
| Q4 25 | $139.2M | $-140.0M | ||
| Q3 25 | $134.2M | $269.3M | ||
| Q2 25 | $122.0M | $274.8M | ||
| Q1 25 | $114.8M | $241.7M | ||
| Q4 24 | $117.5M | $-66.2M | ||
| Q3 24 | $119.8M | $229.4M | ||
| Q2 24 | $107.2M | $240.5M |
| Q1 26 | — | $81.7M | ||
| Q4 25 | $49.4M | $81.7M | ||
| Q3 25 | $36.4M | $9.3M | ||
| Q2 25 | $34.2M | $16.7M | ||
| Q1 25 | $26.9M | $12.4M | ||
| Q4 24 | $111.9M | $5.6M | ||
| Q3 24 | $35.9M | $2.5M | ||
| Q2 24 | $32.1M | $10.9M |
| Q1 26 | — | 12.8% | ||
| Q4 25 | 63.8% | — | ||
| Q3 25 | 56.3% | 12.8% | ||
| Q2 25 | 55.1% | 13.8% | ||
| Q1 25 | 53.2% | 13.6% | ||
| Q4 24 | 53.9% | — | ||
| Q3 24 | 49.8% | 15.4% | ||
| Q2 24 | 53.6% | 14.4% |
| Q1 26 | — | 5.7% | ||
| Q4 25 | 45.1% | — | ||
| Q3 25 | 38.0% | 6.2% | ||
| Q2 25 | 35.1% | 9.9% | ||
| Q1 25 | 30.4% | 9.0% | ||
| Q4 24 | 32.6% | — | ||
| Q3 24 | 33.1% | 3.6% | ||
| Q2 24 | 36.6% | 7.4% |
| Q1 26 | — | 31.9% | ||
| Q4 25 | 35.5% | -58.4% | ||
| Q3 25 | 27.1% | 3.5% | ||
| Q2 25 | 28.1% | 6.1% | ||
| Q1 25 | 23.4% | 5.1% | ||
| Q4 24 | 95.2% | -8.5% | ||
| Q3 24 | 30.0% | 1.1% | ||
| Q2 24 | 29.9% | 4.5% |
| Q1 26 | — | $2.03 | ||
| Q4 25 | $0.20 | $2.01 | ||
| Q3 25 | $0.15 | $0.23 | ||
| Q2 25 | $0.14 | $0.41 | ||
| Q1 25 | $0.11 | $0.30 | ||
| Q4 24 | $0.45 | $0.14 | ||
| Q3 24 | $0.15 | $0.06 | ||
| Q2 24 | $0.13 | $0.27 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $87.6M | $30.0M |
| Total DebtLower is stronger | $72.1M | — |
| Stockholders' EquityBook value | $477.3M | $705.6M |
| Total Assets | $624.2M | $1.5B |
| Debt / EquityLower = less leverage | 0.15× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $30.0M | ||
| Q4 25 | $87.6M | $30.0M | ||
| Q3 25 | $61.4M | $33.6M | ||
| Q2 25 | $90.3M | $30.3M | ||
| Q1 25 | $71.6M | $32.7M | ||
| Q4 24 | $103.1M | $23.1M | ||
| Q3 24 | $86.7M | $26.9M | ||
| Q2 24 | $88.2M | $35.0M |
| Q1 26 | — | — | ||
| Q4 25 | $72.1M | $469.2M | ||
| Q3 25 | $72.4M | $407.1M | ||
| Q2 25 | — | $424.5M | ||
| Q1 25 | — | $434.2M | ||
| Q4 24 | $72.3M | $398.1M | ||
| Q3 24 | — | $409.9M | ||
| Q2 24 | — | $427.4M |
| Q1 26 | — | $705.6M | ||
| Q4 25 | $477.3M | $705.6M | ||
| Q3 25 | $431.2M | $725.0M | ||
| Q2 25 | $398.3M | $715.3M | ||
| Q1 25 | $373.4M | $686.6M | ||
| Q4 24 | $349.0M | $667.3M | ||
| Q3 24 | $231.9M | $682.8M | ||
| Q2 24 | $188.3M | $675.9M |
| Q1 26 | — | $1.5B | ||
| Q4 25 | $624.2M | $1.5B | ||
| Q3 25 | $568.7M | $1.4B | ||
| Q2 25 | $558.4M | $1.4B | ||
| Q1 25 | $510.6M | $1.4B | ||
| Q4 24 | $488.7M | $1.3B | ||
| Q3 24 | $390.6M | $1.4B | ||
| Q2 24 | $376.4M | $1.4B |
| Q1 26 | — | — | ||
| Q4 25 | 0.15× | 0.66× | ||
| Q3 25 | 0.17× | 0.56× | ||
| Q2 25 | — | 0.59× | ||
| Q1 25 | — | 0.63× | ||
| Q4 24 | 0.21× | 0.60× | ||
| Q3 24 | — | 0.60× | ||
| Q2 24 | — | 0.63× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $35.6M | $117.5M |
| Free Cash FlowOCF − Capex | $34.6M | $36.8M |
| FCF MarginFCF / Revenue | 24.8% | 14.4% |
| Capex IntensityCapex / Revenue | 0.8% | 18.9% |
| Cash ConversionOCF / Net Profit | 0.72× | 1.44× |
| TTM Free Cash FlowTrailing 4 quarters | $27.8M | $109.7M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $117.5M | ||
| Q4 25 | $35.6M | $41.5M | ||
| Q3 25 | $13.3M | $36.5M | ||
| Q2 25 | $21.1M | $30.3M | ||
| Q1 25 | $-19.7M | $9.2M | ||
| Q4 24 | $50.2M | $27.1M | ||
| Q3 24 | $25.0M | $22.0M | ||
| Q2 24 | $45.6M | $18.4M |
| Q1 26 | — | $36.8M | ||
| Q4 25 | $34.6M | $36.8M | ||
| Q3 25 | $-1.1M | $22.8M | ||
| Q2 25 | $18.7M | $13.2M | ||
| Q1 25 | $-24.4M | $-3.8M | ||
| Q4 24 | $47.5M | $12.1M | ||
| Q3 24 | $24.0M | $10.2M | ||
| Q2 24 | $43.6M | $7.5M |
| Q1 26 | — | 14.4% | ||
| Q4 25 | 24.8% | -26.3% | ||
| Q3 25 | -0.8% | 8.5% | ||
| Q2 25 | 15.3% | 4.8% | ||
| Q1 25 | -21.2% | -1.6% | ||
| Q4 24 | 40.4% | -18.3% | ||
| Q3 24 | 20.0% | 4.4% | ||
| Q2 24 | 40.7% | 3.1% |
| Q1 26 | — | 18.9% | ||
| Q4 25 | 0.8% | -3.4% | ||
| Q3 25 | 10.7% | 5.1% | ||
| Q2 25 | 2.0% | 6.2% | ||
| Q1 25 | 4.1% | 5.4% | ||
| Q4 24 | 2.3% | -22.6% | ||
| Q3 24 | 0.9% | 5.2% | ||
| Q2 24 | 1.9% | 4.5% |
| Q1 26 | — | 1.44× | ||
| Q4 25 | 0.72× | 0.51× | ||
| Q3 25 | 0.36× | 3.92× | ||
| Q2 25 | 0.62× | 1.81× | ||
| Q1 25 | -0.73× | 0.74× | ||
| Q4 24 | 0.45× | 4.80× | ||
| Q3 24 | 0.70× | 8.71× | ||
| Q2 24 | 1.42× | 1.68× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ADMA
| ADMA Bio Manufacturing Segment | $123.1M | 88% |
| Other | $16.0M | 12% |
TRS
Segment breakdown not available.
